Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL)Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 studyPrioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2...
07.11.2023 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 ...
Adicet Bio (NASDAQ:ACET – Get Free Report) will announce its earnings results on Monday, November 6th. Adicet Bio (NASDAQ:ACET – Get Free Report) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.07). On average, analysts expect […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31,...